Format

Send to

Choose Destination
Expert Opin Ther Targets. 2017 Nov;21(11):1027-1036. doi: 10.1080/14728222.2017.1386175. Epub 2017 Oct 5.

STXBP1 as a therapeutic target for epileptic encephalopathy.

Author information

1
a Neurogenetics Group, Center for Molecular Neurology , VIB , Antwerp , Belgium.
2
b Laboratory of Neurogenetics , Institute Born-Bunge, University of Antwerp , Antwerp , Belgium.
3
c Department of Neurology , Antwerp University Hospital , Antwerp , Belgium.

Abstract

STXBP1 is an essential protein for presynaptic vesicle release. Mutations in STXBP1 have been associated with a series of (epileptic) neurodevelopmental disorders collectively referred to as STXBP1-encephalopathy (STXBP1-E). In this review we hypothesize about the potential of STXBP1 as a therapeutic target in the field of epileptic encephalopathies. Areas covered: A state of the art overview on current understanding of the pathophysiologic mechanism underlying STXBP1-E is presented. Possibilities of different treatment modalities are discussed including unbiased compound screening, specific protein-protein interaction inhibition and gene therapy, consisting either of gene suppletion or upregulation of gene expression. Expert opinion: Current treatment for STXBP1-E is largely limited to seizure control and future therapies will need to target the developmental aspects of the disease as well. Both in vitro- and animal models used to study the pathophysiology of STXBP1-E could be further optimized as a model for compound screening. They should reflect both the hyper excitable state and the psychomotor delay of STXBP1-E. Specific protein-protein interaction and gene therapy are promising future treatment options that need to be investigated further. We suggest a parallel research strategy on basic pathophysiology and compound development with both fields working in close collaboration with the patient/clinical community.

KEYWORDS:

Epileptic encephalopathy; MUNC18-1; STXBP1; neurodevelopmental disorder; precision medicine; therapeutic target

PMID:
28971703
DOI:
10.1080/14728222.2017.1386175
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center